Derek Archila analyst WELLS FARGO

Currently out of the existing stock ratings of Derek Archila, 172 are a BUY (65.4%), 84 are a HOLD (31.94%), 7 are a SELL (2.66%).

Derek Archila

Work Performance Price Targets & Ratings Chart

Analyst Derek Archila, currently employed at WELLS FARGO, carries an average stock price target met ratio of 50.78% that have a potential upside of 44.31% achieved within 144 days.

Derek Archila’s has documented 508 price targets and ratings displayed on 48 stocks. The coverage is on Healthcare, Energy sectors.

Most recent stock forecast was given on CCCC, C4 Therapeutics  at 22-Sep-2025.

Wall Street Analyst Derek Archila

Analyst best performing recommendations are on EQ (EQUILLIUM).
The best stock recommendation documented was for EQ (EQUILLIUM) at 7/10/2020. The price target of $10 was fulfilled within 3 days with a profit of $6.81 (213.48%) receiving and performance score of 711.6.

Average potential price target upside

AIMT Aimmune Therapeutics AMRN Amarin PLC ASND Ascendis Pharma AS CBAY Cymabay Therapeu IMVT Immunovant  KZR Kezar Life Sciences MNTA Momenta Pharmaceuticals PCRX Pacira Pharmaceuticals RYTM Rhythm Pharmaceuticals SGYP Synergy Pharmaceuticals VNDA Vanda Pharmaceuticals GLPG Galapagos NV ADR ICPT Intercept Pharmaceuticals NGM NGM Biopharmaceuticals PHAS PhaseBio Pharmaceuticals PRNB Principia Biopharma APLS Apellis Pharmaceuticals ARVN Arvinas CCCC C4 Therapeutics  HZNP Horizon Pharma PLC INCY yte KYMR Kymera Therapeutics NRIX Nurix Therapeutics  CABA Cabaletta Bio GLUE Monte Rosa Therapeutics MORF Morphic ARGX argenx NV ADR RXDX Prometheus Biosciences URGN UroGen Pharma Ltd ARNA Arena Pharmaceuticals BPMC Blueprint Medicines Corp ESPR Esperion Therapeutics HRTX Heron Therapeuti TEVA Teva Pharma Industries Ltd ADR ZYNE Zynerba Pharmaceuticals CLDX Celldex Therapeutics DICE Dice Molecules Holdings LLC MOR MorphoSys AG ADR VTYX Ventyx Biosciences ZNTL Zentalis Pharmaceuticals Llc ANAB AnaptysBio ANNX Annexon  EXEL Exelixis VRDN Viridian Therapeutics ZYME Zymeworks Common Stock SLRN ACELYRIN, INC. Common Stock CQP Cheniere Energy Partners LP EQ Equillium

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$18

5 years 1 months 7 days ago
(01-Sep-2020)

3/3 (100%)

$3.19 (21.54%)

78

Hold

$60

5 years 1 months 7 days ago
(31-Aug-2020)

0/19 (0%)

$41.31 (221.03%)

Hold

$34.5

$0.01 (0.03%)

$66

5 years 1 months 7 days ago
(31-Aug-2020)

1/8 (12.5%)

$0.28 (0.82%)

39

Hold

$34.5

$0.01 (0.03%)

$14

5 years 1 months 7 days ago
(31-Aug-2020)

7/7 (100%)

$0.28 (0.82%)

105

Hold

$35

$0.51 (1.48%)

$24

5 years 1 months 7 days ago
(31-Aug-2020)

7/17 (41.18%)

$0.78 (2.28%)

376

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Derek Archila is most bullish on?

Potential upside of $29.98 has been obtained for RYTM (RHYTHM PHARMACEUTICALS)

Which stock is Derek Archila is most reserved on?

Potential downside of -$4.9 has been obtained for KYMR (KYMERA THERAPEUTICS)

What Year was the first public recommendation made by Derek Archila?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?